Status:
TERMINATED
Gene Expression in MS Patients Before and During Treatment With Interferon-beta
Lead Sponsor:
S. Andrea Hospital
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-55 years
Brief Summary
Clinical and experimental evidences suggest that there is a variability in therapeutic response to immunomodulating therapies in Multiple Sclerosis patients. Microarrays is a technology that permits ...
Eligibility Criteria
Inclusion
- diagnosis of relapsing-remitting MS (McDonald criteria)
- age between 18-55
- EDSS less or equal to 5.5
Exclusion
- use of any other disease modifying drugs
- use of corticosteroids during 3 months before starting protocol
- clinical relapse during 1 month before starting protocol
- serious heart, renal, hepatic or haematological dysfunction defined by laboratory exams
Key Trial Info
Start Date :
November 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT00202384
Start Date
November 1 2004
End Date
January 1 2011
Last Update
April 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera S. Andrea, II Facoltà di Medicina e Chirurgia, Università di Roma "La Sapienza"
Rome, Italy, 00100